[Alphabiz=(Chicago) Reporter Kim Jisun] Biopharmaceutical company Medytox (CEO Chung Hyun-ho) signed a memorandum of understanding (MOU) on the construction of a toxin finished product plant with Marwan Abdulaziz Janahi, owned by Dubai's state-run Tecom Group at the Korea-UAE Business Forum held at the Rixos Marina Hotel in Abu Dhabi, the United Arab Emirates (UAE) on the 16th (local time).
With the signing of the MOU, Medytox will build a production facility based on the liquid toxin drug "MT10109L" in Dubai, and plans to target the global Muslim market and the Middle Eastern and European markets through HALAL certification.
Meanwhile, when Medytox builds a toxin finished product production facility in Dubai, it will be the first Korean company to have a toxin production facility overseas. With this MOU as an opportunity, Medytox has begun detailed consultations on future implementation measures and plans to sign the contract once discussions are completed
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
